British pharmaceutical giant GSK has not met required ethical and regulatory standards in its marketing and prescription information for its Omjjara drug, an industry self-regulatory body said on Tuesday.
Omjjara is used to treat adults with myelofibrosis - a rare bone marrow blood cancer - and moderate to severe anemia.
GSK did not immediately respond to a Reuters request for comment on the ruling by the Prescription Medicines Code of Practice Authority (PMCPA).
https://uk.finance.yahoo.com/news/gsk-breach-misleading-prescribing-information-084853047.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.